UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 12, 2018

 

 

 

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   000-53078   42-1743430
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

2 Burlington Woods Drive, Ste. 100
Burlington, MA
  01803
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 552-4452

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

 

 

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

Annual Meeting of Stockholders

 

An annual meeting (“Annual Meeting”) of the stockholders of Bone Biologics Corporation, a Delaware corporation (the “Company”), was held on September 12, 2018. The Company filed its definitive proxy statement in connection with the Annual Meeting with the Securities and Exchange Commission on August 10, 2018 (which can be viewed at: www.sec.gov). The Company’s stockholders considered the following proposals at the Annual Meeting:

 

    Proposal I: A proposal to elect Don Hankey, Bruce Stroever, Stephen LaNeve, John Booth and Bret Hankey to the Company’s Board of Directors; and
     
    Proposal II: A proposal to approve on an advisory basis the compensation of the Company’s named executive officers; and
     
    Proposal III: A proposal to ratify the appointment of Weinberg & Company, P.A., as our independent registered public accountant for the fiscal year ending December 31, 2018.

 

Voting Results

 

Proposal I: The election of the directors was approved as follows:

 

    FOR     WITHHELD     BROKER NON-VOTES  
                   
Don Hanky     6,299,217       -       7,003  
                         
Bruce Stroever     5,424,971       874,246       7,003  
                         
Stephen La Neve     5,424,971       874,246       7,003  
                         
John Booth     5,424,971       874,246       7,003  
                         
Bret Hanky     6,299,217       -       7,003  

 

Proposal II: Approval of Executive Compensation was approved with 5,424,971 “FOR” votes, 874,246 “AGAINST” votes, 0 “ABSTAIN” votes and 7,003 broker non-votes.

 

Proposal III: Ratification of the appointment of Weinberg & Company, P.A., as independent registered public accountant for the fiscal year ending December 31, 2018 was approved with 6,306,220 “FOR” votes, 0 “AGAINST” votes and 0 “ABSTAIN” votes.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 14, 2018 Bone Biologics Corporation
     
  By: /s/ STEPHEN R. LaNEVE
  Name: Stephen R. LaNeve
  Title: Chief Executive Officer